Skip Navigation


Brain Advance Access originally published online on April 27, 2005
Brain 2005 128(8):1861-1869; doi:10.1093/brain/awh515
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
128/8/1861    most recent
awh515v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kärppä, M.
Right arrow Articles by Majamaa, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kärppä, M.
Right arrow Articles by Majamaa, K.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2005). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Spectrum of myopathic findings in 50 patients with the 3243A>G mutation in mitochondrial DNA

Mikko Kärppä1,2, Riitta Herva3, Ali-Reza Moslemi5, Anders Oldfors5, Sakari Kakko4 and Kari Majamaa1,2,6

1 Department of Neurology, University of Oulu, 2 Clinical Research Center, 3 Department of Pathology, 4 Department of Internal Medicine, Oulu University Hospital, Oulu, 5 Department of Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden and 6 Department of Neurology, University of Turku, Turku, Finland

Correspondence to: Professor Kari Majamaa, University of Oulu, Department of Neurology, PO Box 5000, FIN-90014 Oulu, Finland E-mail: kari.majamaa{at}oulu.fi

Myopathy is a typical clinical finding among patients with the 3243A>G mutation in mitochondrial DNA (mtDNA), but the variability in such findings has not been properly established. We have previously determined the prevalence of patients with 3243A>G in a defined population in northern Finland and characterized a group of patients who represent a good approximation to a population-based cohort. We report here on examinations performed on patients belonging to this cohort in order to determine the frequency of myopathy and to evaluate the clinical, histological, ultrastructural and single fibre mtDNA variability in muscle involvement. Fifty patients with 3243A>G underwent a thorough structured interview and clinical examination. Muscle histology, ultrastructure and single fibre analysis were examined in a subset of patients. A clinical diagnosis of myopathy was made in 50% of cases [95% confidence interval (CI), 36–64] and abnormalities in muscle histology were found in 72% (95% CI, 55–86). Moderate limb weakness leading to functional impairment was the most common myopathic sign, but mild weakness, ptosis and external ophthalmoplegia could also be found. The presence of intramitochondrial crystals and cytochrome c oxidase (COX)-negative fibres and variation in mitochondrial size and shape were more common in the muscles of the myopathic patients. Longitudinal variations in mutation heteroplasmy were examined in single muscle fibres from two severely affected patients. Although the total variation in mutation heteroplasmy along four ragged red fibres (RRFs) was small, the mutation heteroplasmy in five 10 µm segments was clearly lower (median 68%, range 64–74%) than that in the neighbouring segments. There were also segments with deviant mutation load in histologically normal fibres in one patient. The highest incidence of myopathy was in the fifth decade of life, but, apart from age, no other clinical variables such as gender, muscle heteroplasmy, physical inactivity or diabetes were associated with an increased risk of myopathy. The clinical presentation of myopathy is highly variable in patients with 3243A>G.

Key Words: mitochondrial myopathies; muscle fibres; ultrastructure; clinical laboratory techniques; MELAS

Abbreviations: CI = confidence interval; CK = creatine kinase; COX = cytochrome c oxidase; mtDNA = mitochondrial DNA; RRF = ragged red fibre

Received March 2, 2005. Accepted March 23, 2005.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
DiabetesHome page
M. M. Lindroos, K. Majamaa, A. Tura, A. Mari, K. K. Kalliokoski, M. T. Taittonen, P. Iozzo, and P. Nuutila
m.3243A>G Mutation in Mitochondrial DNA Leads to Decreased Insulin Sensitivity in Skeletal Muscle and to Progressive {beta}-Cell Dysfunction
Diabetes, March 1, 2009; 58(3): 543 - 549.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
T. D. Jeppesen, M. Schwartz, A. L. Frederiksen, F. Wibrand, D. B. Olsen, and J. Vissing
Muscle Phenotype and Mutation Load in 51 Persons With the 3243A>G Mitochondrial DNA Mutation
Arch Neurol, December 1, 2006; 63(12): 1701 - 1706.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
K.A.M. Majamaa-Voltti, S. Winqvist, A. M. Remes, U. Tolonen, J. Pyhtinen, S. Uimonen, M. Karppa, M. Sorri, K. Peuhkurinen, and K. Majamaa
A 3-year clinical follow-up of adult patients with 3243A>G in mitochondrial DNA
Neurology, May 23, 2006; 66(10): 1470 - 1475.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.